## **Disclosure of Potential Conflicts of Interest List**

## <u>NOTE:</u> The scientific program, in both content and speaker selection, is developed independently of any commercial interests or pharmaceutical affiliations.

| First name  | Last name            | Country        | Disclosures   |
|-------------|----------------------|----------------|---|
| Adly        | Sabbour              | Egypt          | To be confirmed   |
| Adolfo      | Llinas               | Colombia       | Bayer (speaker); 3M (Patents N=2);<br>Immo Med (Royalties)  |
| Adriana     | Linares              | Colombia       | Takeda (conference honorarium); Bayer (conference honorarium)   |
| Alain       | Baumann              | Canada         | Nothing to disclose   |
| Alessandro  | Casini               | Switzerland    | LFB (personal fees); Takeda<br>(personal fees); Octapharma (grant);<br>Sobi (non-financial support and<br>personal fees); Novo Nordisk (non-<br>financial support)  |
| Alfonso     | lorio                | Canada         | Bayer, CSL, NovoNordisk, Pfizer,<br>Roche, Sanofi, Sobi, and Takeda.<br>(Alfonso Iorio's institution,<br>McMaster University, has received<br>project based funding via research<br>service agreements and research<br>grants from)   |
| Alison      | Dougall              | Ireland        | To be confirmed   |
| Alok        | Srivastava           | India          | To be confirmed   |
| Amanda      | Brito del Pino Mouro | Uruguay        | Nothing to disclose   |
| Ampaiwan    | Chuansumrit          | Thailand       | Novo Nordisk (honoraria); Takeda<br>(honoraria); Sysmex (honoraria);<br>Grifols (honoraria); Roche<br>(honoraria)   |
| Amr         | El-Sayed             | Egypt          | Novo Nordisk Egypt (Employee)   |
| Amy         | Dunn                 | United States  | To be confirmed   |
| Ana         | Torres               | Spain          | Nothing to disclose   |
| Anabela     | Aries                | Portugal       | To be confirmed   |
| Andrea      | Laslop               | Austria        | Nothing to disclose   |
| Andreas     | Tiede                | Germany        | To be confirmed   |
| Anne Louise | Cruickshank          | South Africa   | Roche (grant to attend Congress);<br>Novo Nordisk (grant to attend<br>Congress; Advisory board)   |
| Annette     | Bowyer               | United Kingdom | Roche (Honoraria); Pfizer<br>(Honoraria)  |
| Annette     | Von Drygalski        | United States  | CSL Behring (advisory board); Regeneron (advisory board); Biomarin (advisory board); Sanofi (advisory board; research support); Novo Nordisk (advisory board); Precision Medicine (advisory board); Pfizer (advisory board); Genentech (advisory board); Uniqure (advisory board); Takeda (advisory board); |

| Annick    | Ndoumba Nkengue | Cameroon       | Nothing to disclose  |
|-----------|-----------------|----------------|--|
| Antonio   | Gavrilovski     | Macedonia      | To be confirmed  |
| April     | Jones           | United Kingdom | Pfizer (advisory board); Novo<br>Nordisk (speaker fees); Roche<br>(sponsorship to attend this meeting)   |
| Apsara    | Boadas          | Venezuela      | Nothing to disclose  |
| Assad     | Haffar          | Canada         | To be confirmed  |
| Augusto   | Federici        | Italy          | CSL Behring (personal fees for advisory boards); Grifols (personal fees for advisory boards); Takeda (personal fees for advisory boards)   |
| Barbara   | Konkle          | United States  | BioMarin (Consultation (DMC)(personal)); Novo Nordisk (Consultation (DMC)(personal)); Pfizer (Consultation(personal), Research support (institution)); Sanofi (Consultation(personal), Research support (institution)); Takeda (Research support (institution)); Hemab (Research support (institution)); Regeneron (Consultation(personal)); Be Biopharma (Consultation(personal)); Genentech/Roche (Research support (institution)) |
| Benjamin  | Kim             | United States  | Vega Therapeutics, Inc. (Employee)   |
| Bishesh   | Poudyal         | Nepal          | Nothing to disclose  |
| Branislav | Bajkin          | Serbia         | To be confirmed  |
| Brian     | O'Mahony        | Ireland        | Biomarin (speaker fees); CSL Behring (speaker fees); Bayer (advisory board)  |
| Brian     | Ramsay          | New Zealand    | Sanofi (Grant: Sponsorship to attend ISTH Congress in Montreal 2023); Roche (Grant; Sponsorship of Accommodation for WFH Congress 2024)  |
| Bridget   | Yates           | United States  | BioMarin Pharmaceutical Inc.<br>(Employee, Ownership or<br>Partnership)  |
| Bruno     | Steiner         | United States  | Sanofi (research funding); Roche<br>(research funding); CSL Behring<br>(consultation and research funding)   |
| Cameron   | Cramey          | Australia      | Nothing to disclose  |
| Carla     | Daffunchio      | Argentina      | Nothing to disclose  |
| Carlos    | Cruz Montecinos | Chile          | Nothing to disclose  |
| Carlos    | Safadi Marquez  | Argentina      | To be confirmed  |
| Caroline  | Malcolmson      | Canada         | Sanofi (Research Funding, Speaker<br>funding); Roche (research funding);<br>Takeda (Advisory board); Bayer   |

|           |          |                | 1  |
|-----------|----------|----------------|--|
| Catherine | Hayward  | Canada         | (Advisory board; research funding); Canadian Pediatric Thrombosis Hemoastasis Network (Research funding); Canadian Hemophilia Society (research funding); Novo Nordisk (Education support); Octapharma (Education support) Werfen (honoraria; scientific advisory board); Stago (honoraria; scientific advisory board); UpToDate (royalties)   |
| Cathy     | Harrison | United Kingdom | CSL (Conference sponsorship; consultancy fee); Novo Nordisk (consultancy fee); Pfizer (consultancy fee); Roche-Chugai (conference sponsorship; consultancy fee); Sobi (consultancy fee); Takeda (conference sponsorship); Sanofi (consultancy fee)   |
| Cathy     | Tiggs    | United States  | Novo Nordisk (speakers bureau)   |
| Cedric    | Hermans  | Belgium        | To be confirmed  |
| Cesar     | Garrido  | Venezuela      | To be confirmed  |
| Cesar     | Haddad   | Lebanon        | Nothing to disclose  |
| Cheryl    | Alexis   | Barbados       | Nothing to disclose  |
| Christian | Carulli  | Italy          | Nothing to disclose  |
| Christina | Vosl     | Austria        | Nothing to disclose  |
| Christine | Lynn     | United Kingdom | Nothing to disclose  |
| Christoph | Königs   | Germany        | Bayer (clinical trials and/or research funding to university; speakers' bureau/advise); Biotest (clinical trials and/or research funding to university); CSL Behring (clinical trials and/or research funding to university; speakers' bureau/advise); Intersero (clinical trials and/or research funding to university); Novo Nordisk (clinical trials and/or research funding to university; speakers' bureau/advise); Pfizer (clinical trials and/or research funding to university); Roche/Chugal (clinical trials and/or research funding to university; speakers' bureau/advise); Sobi/Sanofi (clinical trials and/or research funding to university; speakers' bureau/advise); Takeda (clinical trials and/or research funding to university; speakers' bureau/advise); BFSH (speakers' bureau/advise); BFSH (speakers' bureau/advise); Florio (speakers' |

|          |                   | <u> </u>       | bureau/advise); MSD (speakers'  |
|----------|-------------------|----------------|---|
|          |                   |                | bureau/advise);   |
| Cindy    | Bailey            | United States  | Sanofi (speaker – joint health –<br>honoraria); CSL Behring (ultrasound<br>reader – honoraria)  |
| Claudia  | Djambas Khayat    | Lebanon        | CSL (personal fee - lectures, Nm financial support – travel); Octapharma (personal fee - lectures, Nm financial support – travel)   |
| Clive    | Smith             | United Kingdom | Pfizer (personal fees); Takeda (personal fees); Alphasights (personal fees); Sobi (personal fees); Roche (personal fees); Haemnet (personal fees); BioMarin (personal fees); Sanofi (personal fees); Future Health (personal fees);   |
| Cristina | Catarino Oliveira | Portugal       | Roche (personal fee/non-financial support); Sobi (personal fee/non-financial support); Novo Nordisk (personal fee/non-financial support); CSL Behring (personal fee/non-financial support); Bayer (personal fee/non-financial support); Octapharma (personal fee/non-financial support) |
| Curtis   | Yee               | United States  | Nothing to disclose   |
| Cyrus    | Njuguna Githinjii | Kenya          | Nothing to disclose   |
| Daan     | Breederveld       | Netherlands    | To be confirmed   |
| Darrel   | Stafford          | United States  | To be confirmed   |
| David    | Lillicrap         | Canada         | Biomarin (research support and advisory role); CSL (advisory role); Novo Nordisk (advisory role); Pfizer (advisory role); Sanofi (research support and advisory role)   |
| David    | Page              | Canada         | Nothing to disclose   |
| Davide   | Matino            | Canada         | Bayer (Advisor, Consultant); Novo<br>Nordisk (Advisor, Consultant);<br>Octapharma (Advisor, Consultant);<br>Pfizer (Advisor, Consultant); Roche<br>(Consultant); Sanofi (Advisor,<br>Consultant); Sobi (Advisor,<br>Consultant); Spark (Consultant)                                     |
| Dawn     | Rotellini         | United States  | Roche (Honoraria - all goes directly<br>to NBDF); BioMarin (Honoraria - all<br>goes directly to NBDF); Sanofi<br>(Honoraria - all goes directly to<br>NBDF)   |
| Diana    | Lighezan          | Romania        | Nothing to disclose   |
| Diane    | Standish          | United States  | Nothing to disclose   |
| Donna    | Coffin            | Canada         | To be confirmed   |

|              |              |               | Bayer (consulting); Biomarin<br>(Consulting/Speaker's Bureau); CSL  |
|--------------|--------------|---------------|---|
| Doris        | Quon         | United States | Behring (Consulting/Speaker's Bureau); Hemabiologics/LFB (Consulting/Speaker's Bureau); Genentech/Roche (Consulting); Novo Nordisk (Consulting/Speaker's Bureau); Pfizer (Consulting/Speaker's Bureau); Sanofi (Consulting/Speaker's Bureau); Takeda (consulting)   |
| Ekawat       | Suwantaroj   | Thailand      | Nothing to disclose   |
| Elena        | Donoso Ubeda | Spain         | Nothing to disclose   |
| Eline        | Van Bergen   | Netherlands   | Nothing to disclose   |
| Elizabete    | Pumpure      | Latvia        | Nothing to disclose   |
| Elizabeth    | Clearfield   | United States | Nothing to disclose   |
| Ellia        | Tootoonchian | Canada        | Nothing to disclose   |
| Maria Elvira | Correa       | Brazil        | Nothing to disclose   |
| Emily        | Ayoub        | Canada        | Nothing to disclose   |
| Emna         | Gouider      | Tunisia       | To be confirmed   |
| Eric         | Chang        | United States | Nothing to disclose   |
| Erica        | Crilly       | Canada        | Sanofi (honoraria – advisory board);<br>Octapharma (speaker fees); Pfizer<br>(speaker fees)   |
| Evelien      | Krumb        | Belguim       | CSL Behring (financial research support); Swedish Orphan Biovitrum (Sobi) (financial research support); BioMarin (speaker honorarium)   |
| Flora        | Peyvandi     | Italy         | Takeda/Spark (Participation in educational meetings or symposia); Sanofi (Participation in advisory boards); Sobi (Participation in advisory boards); CSL Behring (Participation in advisory boards); Biomarin (Participation in advisory boards); Roche (Participation in advisory boards)                                   |
| Frank        | Leebeek      | Netherlands   | CSL Behring (unrestricted research grant; consultant fees to the university); Sobi (unrestricted research grant); Takeda (unrestricted research grant; webinar and consultant fees to the university); Uniqure (unrestricted research grant; consultant fees to the university); Biomarin (consultant fees to the university) |
| Fred         | Loeffler     | United States | Novo Nordisk Hemophilia Foundation: India 13 MSK Project (grant); Sanofi Genzyme: Joint and Bone Health in Hemophilia (personal fees)   |

| Gabrielle | Flores    | United States | Nothing to disclose  |
|-----------|-----------|---------------|--|
| Gaby      | Golan     | Israel        | Nothing to disclose  |
| Geneviève | McCluskey | France        | Nothing to disclose  |
| Geoff     | McDonough | United States | To be confirmed  |
| Giancarlo | Castaman  | Italy         | Bayer (personal fee); Biomarin<br>(personal fee); Bioviix (personal<br>fee); CSL Behring (personal fee); LFB<br>(personal fee); Pfizer (personal fee);<br>Roche (personal fees); SOBI<br>(personal fees); Takeda (personal<br>fees)  |
| Gianluigi | Pasta     | Italy         | Bayer Spa (Personal fees); Novo<br>Nordisk (Personal fees); Pfizer<br>(Personal fees); Roche (Personal<br>fees); Sobi (Personal fees); Takeda<br>(Personal fees)   |
| Glenda    | Feldberg  | Brazil        | Nothing to disclose  |
| Glenn     | Pierce    | United States | BioMarin (consultant); Be Biopharma (scientific advisory board); Frontera (scientific advisory board); Metagenomi (scientific advisory board); Novo Nordisk (consultant); Regeneron (consultant); Spark Therapeutics (consultant) Genentech (consultant); Third Rock Ventures (entrepreneur in residence); World Federation of Hemophilia (director); Voyager Therapeutics (director); National Bleeding Disorders Foundation Medical and Scientific Advisory Council (member) |
| Grace     | Hernandez | United States | Sanofi Genzyme (speaker bureau);<br>Takeda (speaker bureau)  |
| Greig     | Blamey    | Canada        | To be confirmed  |
| Greta     | Mulders   | New Zealand   | CSL Behring (speaker fee); Novo<br>Nordisk (consultant fee); Sobi<br>(Research grant)  |
| Guy       | Young     | United States | Bayer (Advisor, Consultant) BioMarin (Advisor, Consultant) Centessa (Consultant) CSL Behring (Advisor, Consultant) Freeline (Advisor, Consultant) Genentech, Inc. (Advisor, Research Grant) Genentech, Inc./F. Hoffmann-La Roche Ltd. (Advisor, Consultant, Research Grant) Grifols (Research Grant) HEMA Biologics (Advisor) LFB (Consultant) Novo Nordisk (Advisor, Consultant) Octapharma (Advisor, Consultant)   |

|                 |                       |                | Pfizer (Advisor, Consultant) Sanofi (Advisor, Consultant, Research Grant) Spark Therapeutics, Inc. (Advisor, Consultant) Takeda (Advisor, Consultant, Research Grant) Viatris (Ownership or Partnership)  |
|-----------------|-----------------------|----------------|---|
| Hadeel Saleh    | Mohammad              | Kuwait         | To be confirmed   |
| Hanny           | Al Samkari            | United States  | Agios (consultancy; research funding to institution); Amgen (consultancy; research funding to institution); Novartis (consultancy; research funding to institution); Sobi (consultancy; research funding to institution); Vaderis (research funding to institution); Argenx (consultancy); Forma (consultancy); Moderna (consultancy); Pharmacosmos (consultancy) |
| Haroon          | Mann                  | United Kingdom | To be confirmed   |
| Hazri           | Aris                  | Malaysia       | Nothing to disclose   |
| Heather         | Perkins               | Canada         | Nothing to disclose   |
| Horacio         | Caviglia              | Argentina      | To be confirmed   |
| Hortensia       | de la Corte Rodriguez | Spain          | Nothing to disclose   |
| Huyen Tran      | Tran                  | Australia      | NovoNordisk (Education/speaker honorarium; consulting fees); Pfizer (Education/speaker honorarium; consulting fees); Sanofi (research grant; consulting fees); Biomarin (consulting fees); CSLB (consulting fees); TGA (consulting fees)  |
| Inmaculada      | Soto                  | Spain          | To be confirmed   |
| lan             | Jennings              | United Kingdom | Nothing to disclose   |
| James           | Luck                  | United States  | Nothing to disclose   |
| Jan             | Blatny                | Czech Republic | Novo Nordisk (Consultation and/or speaker's fees); Roche (Consultation and/or speaker's fees); Takeda (Consultation and/or speaker's fees); CSL Behring (Consultation and/or speaker's fees); Sobi (Consultation and/or speaker's fees)   |
| Jan             | Glazewski             | South Africa   | Nothing to disclose   |
| Jane            | Portnoy               | Australia      | Nothing to disclose   |
| Jean Christophe | Gris                  | France         | Nothing to disclose   |
| Jeffrey         | Kallberg              | United States  | Bayer healthcare (paid speaker);<br>Sanofi (speaker/consultant);<br>Genentech (research grant)  |

| Jennifer       | Maahs            | United States  | Nothing to disclose  |
|----------------|------------------|----------------|--|
| Jenny          | Goudemand        | France         | LFB Biotechnologies (Board<br>Member/Officer/Trustee)<br>Roche-Chugai (Consultant)   |
| Jill           | Johnsen          | United States  | To be confirmed  |
| John           | Weisel           | United States  | To be confirmed  |
| Johnny         | Mahlangu         | South Africa   | BioMarin (research grant, advisory board/consultant); NovoNordisk (research grant, advisory board/consultant); Pfizer (research grant, advisory board/consultant); Roche (research grant, advisory board/consultant); Sanofi (research grant, advisory board/consultant); Spark (research grant, advisory board/consultant); Takeda (research grant, advisory board/consultant); Vega (research grant, advisory board/consultant); Regeneron (advisory board/consultant) |
| Jose           | Lora             | United States  | To be confirmed  |
| Joseph John    | Manthanathu      | India          | Roche (Advisory board<br>member/Speaker fee); Novo<br>Nordisk (Advisory board member);<br>Pfizer (Advisory board member);<br>Takeda (Advisory board<br>member/speaker fee)   |
| Juan Andrés    | Pereira de Sousa | Uruguay        | Nothing to disclose  |
| Karen          | Strike           | Canada         | Novo Nordisk (consultancy); Bayer<br>(consultancy); Hemophilia Ontario<br>(consultancy); Sanofi (consultancy);<br>Hemalytic (consultancy); Takeda<br>(consultancy)   |
| Karola         | Diósi            | Hungary        | Nothing to disclose  |
| Kate           | Khair            | United Kingdom | Haemnet (shareholder/owner)  |
| Kathaleen      | Schnur           | United States  | Nothing to disclose  |
| Kathelijn      | Fischer          | Netherlands    | Bayer (consultancy; research grants; education lectures; travel support); Biogen (consultancy); CSL Behring (consultancy); Novo Nordisk (consultancy; research grants; educational lectures); Sobi (consultancy; travel support); Pfizer (research grants; educational lectures)   |
| Krishnan       | Viswanadhan      | United States  | To be confirmed  |
| Latifa Lamhene | Lamhene          | Algeria        | Nothing to disclose  |
| Laura Beatriz  | Isidro Olán      | Mexico         | Nothing to disclose  |
| Laura          | McDonald         | Canada         | Nothing to disclose  |

| Lauren   | Phillips            | New Zealand    | To be confirmed   |
|----------|---------------------|----------------|---|
| Laurence | Boma-Fischer        | Canada         | To be confirmed   |
| Laurence | Woollard            | United Kingdom | On The Pulse Consultancy Ltd. (owner/100% shareholder)  |
| Laurent  | Frenzel             | France         | Ad Scientiam (Consultant) BioMarin (Advisor) CSL Behring (Advisor) Pfizer (Advisor) Roche (Advisor)   |
| Leonard  | Valentino           | United States  | To be confirmed   |
| Liliana  | Rossetti            | Argentina      | Nothing to disclose   |
| Lisa     | Littner             | United States  | Nothing to disclose   |
| Lize     | Van Vulpen          | Netherlands    | Grifols (grant – paid to institution);<br>Novo Nordisk (grant – paid to<br>institution)   |
| Lochana  | Nanayakkara         | United Kingdom | Nothing to disclose   |
| Luigi    | Solimeno            | Italy          | CSL Behring (personal fees); Sobi (personal fees)   |
| Luke     | Pembroke            | United Kingdom | Haemnet Ltd (shareholder)   |
| Magdy    | El Ekiaby           | Egypt          | To be confirmed   |
| Mahmoud  | Abu-Riash           | Saudi Arabia   | To be confirmed   |
| Maj      | Friberg Birkedal    | Denmark        | CSL Behring (Advisory board member; personal fee); Novo Nordisk (consultant; personal fee); Sobi (consultant; scientific steering committee member; personal fee); Takeda (consultant; personal fee)  |
| Maja     | Sondergaard Knudsen | Denmark        | Nothing to disclose   |
| Manuel   | Carcao              | Canada         | Bioverativ/Sanofi (Research Support; honoraria for speaking/participating in advisory boards); Novartis (research support); Novo Nordisk (Research support; honoraria for speaking/participating in advisory boards); Pfizer (Research support; honoraria for speaking/participating in advisory boards); Roche (Research support); Shire/Takeda (Research support); Shire/Takeda (Research support; honoraria for speaking/participating in advisory boards); Bayer (honoraria for speaking/participating in advisory boards); LFB (honoraria for speaking/participating in advisory boards) |
| Manuela  | Carvalho            | Portugal       | To be confirmed   |
| Manuel   | Rodríguez López     | Spain          | Octapharma (advisory board);<br>Roche (advisory board); Sobi  |

|              |               |               | (advisory board); Novo Nordisk (advisory board); CSL Behring (advisory board)  Biomarin (Research grant and clinical trial support for my Institution.; Personal fees as speaker, and as member of advisory committee); Bayer (Personal fees as speaker, and as member of advisory committee); Novo Nordisk (Clinical trial support for my Institution; Personal fees as speaker, and as member of advisory committee.); Pfizer (Research grant and clinical trial support for my Institution.; Personal fees as speaker, and as |
|--------------|---------------|---------------|--|
| Margareth    | Ozelo         | Brazil        | consultant.); Roche (Research grant and clinical trial support for my Institution.; Personal fees as speaker, and as member of advisory committee) Sanofi (Clinical trial support for my Institution.; Personal fees as speaker, and as member of advisory committee.); Takeda (Research grant and clinical trial support for my Institution.; Personal fees as speaker, and as member of advisory committee)  |
| Maria Elisa  | Mancuso       | Italy         | Bayer (unrestricted grant; personal fees); Biomarin (personal fees); CSL Behring (unrestricted grant; personal fees); Kedrion (personal fees); Novo Nordisk (unrestricted grant; personal fees); Octapharma (personal fees); Pfizer (personal fees); Roche (personal fees); Sanofi (personal fees); Sobi (personal fees); Takeda (unrestricted grants; personal fees)  |
| María        | Landro        | Argentina     | Nothing to disclose  |
| Maria        | Santaella     | United States | Nothing to disclose  |
| Maria Teresa | Álvarez Román | Spain         | Novo Nordisk (speaker, in advisory boards and sponsored symposia); Takeda (speaker, in advisory boards and sponsored symposia); Roche (speaker, in advisory boards and sponsored symposia); Pfizer (speaker, in advisory boards and sponsored symposia); Octapharma (speaker, in advisory boards and sponsored symposia); Amgen (speaker, in advisory boards and sponsored symposia); Novartis (speaker, in advisory boards and  |

| Maria-Eva      | Mingot-Castellano | Spain         | sponsored symposia); CSL Behring (speaker, in advisory boards and sponsored symposia); Sobi (speaker, in advisory boards and sponsored symposia)  Novonordisk (Receipt of grants/research supports; Receipt of honoraria or consultation fees; Participation in a company sponsored speaker's bureau); Takeda (Receipt of grants/research supports; Receipt of honoraria or consultation fees; Participation in a company sponsored speaker's bureau); Grifols (Receipt of grants/research supports; Receipt of honoraria or consultation fees; Participation in a company sponsored speaker's bureau); Amgen (Receipt of grants/research supports; Receipt of honoraria or consultation fees; Participation in a company sponsored speaker's bureau); Sanofi (Receipt of grants/research supports; Receipt of honoraria or consultation fees; Participation in a company sponsored speaker's bureau); Sobi (Receipt of honoraria or consultation fees; Participation in a company sponsored speaker's bureau); Novartis (Receipt of honoraria or consultation fees; Participation in a company sponsored speaker's bureau); Novartis (Receipt of honoraria or consultation fees; Participation in a company sponsored speaker's bureau); Sobi of honoraria or consultation fees; Participation in a company sponsored speaker's bureau); Novartis (Receipt of honoraria or consultation fees; Participation in a company sponsored speaker's bureau) |
|----------------|-------------------|---------------|---|
| Mark           | Krimmel           | United States | Sanofi (Speaker bureau; consultancy and honoraria); Pfizer (other: research funding); Bioverativ (other: research funding); Genentech (other: research funding)   |
| Maria Victoria | Hernández         | Argentina     | Nothing to disclose   |
| Mark           | Skinner           | United States | MS institution received research support for the PROBE study and core outcomes studies as part of an independent investigator-initiated research project. His Institution has received research  Support, honoraria or fees from: Band Therapeutics, Bayer, Biomarin, CSL, Novo Nordisk, Roche/Genentech, Pfizer, Sanofi,   |

|               |            |                | Takeda and Vega Therapeutics.   |
|---------------|------------|----------------|---|
|               |            |                | MS serves on advisory or<br>governance boards of Blue Cross<br>Blue Shield MAP, ICER, NHF MASAC,<br>NORD, WFH USA, Pfizer (DSMB) and<br>Spark (DSMB).   |
| Marko         | Marinić    | Croatia        | Nothing to disclose   |
| Marlène       | Beijlevelt | Netherlands    | Nothing to disclose   |
| Mauricio      | Silva      | United States  | Nothing to disclose   |
| Maya          | Bloomberg  | United States  | Pfizer (advisory board); Genentech<br>(advisory board; consultant); Novo<br>Nordisk (advisory board); Sanofi<br>(advisory board); Takeda (advisory<br>board); Apellis (consultant)  |
| Megan         | Adediran   | Nigeria        | To be confirmed   |
| Megan         | Chaigneau  | Canada         | Novo Nordisk (Research Grant)   |
| Megan Kennedy | Kennedy    | Ireland        | Takeda Pharmaceutical Company (Served on an advisory council to Takeda.)  |
| Meila Roy     | Roy        | United Kingdom | Nothing to disclose   |
| Merel Timmer  | Timmer     | Netherlands    | Sobi (consultancy – paid to the institution); CSL (consultancy – paid to the institution); Novo Nordisk (grant – paid to the institution)   |
| Michael       | Makris     | United Kingdom | Grifols (consultancy); Novo Nordisk (consultancy); Sanofi (consultancy); Takeda (consultancy)   |
| Michael       | Shu        | Canada         | Canadian Pediatric Thrombosis & Hemostasis Network (Research Grant)   |
| Michael       | Wang       | United States  | BioMarin (Personal fees, Non-<br>Financial Support); CSL Behring<br>(Personal fees, Non-Financial<br>Support); Genetech (Personal fees);<br>Novo Nordisk (Personal fees);<br>Bioverativ (Personal fees, Non-<br>Financial Support); Hema Biologics<br>(Personal fees, Non-Financial<br>Support); Vega Therapeutics<br>(Personal fees); Takeda (Personal<br>fees, Non-Financial Support) |
| Michelle      | Lavin      | Ireland        | CSL Behring (Advisory board,<br>Consultant); Sobi (Consultant,<br>speakers fees); Band Therapeutics<br>(Consultant); Takeda (Consultant,<br>speakers fees, research funding)  |
| Michiel       | Coppens    | Netherlands    | Roche (Research support (I am PI on<br>a Roche sponsored study at my<br>centre)); CSL Behring (Research   |

|              |                     |                | support (CSL sponsored study),<br>personal fees for lecturing and<br>consultancy.); Novo Nordisk<br>(Research support); Bayer (Research<br>support); Octapharma (Personal<br>fees (consultancy)); Pfizer (Personal<br>fees for lecturing); Sobi (Personal<br>fees for consultancy) |
|--------------|---------------------|----------------|--|
| Miguel       | Crato               | Portugal       | To be confirmed  |
| Miguel       | Escobar             | United States  | To be confirmed  |
| Minackshi    | Dhurmoo-Luchmun     | Mauritius      | Nothing to disclose  |
| Ming Y Lim   | Lim                 | United States  | Alexion (Honoraria); Sanofi<br>(Honoraria); Takeda (Honoraria)   |
| Miryam       | Parreira            | Argentina      | Nothing to disclose  |
| Mohsena      | Olath-Carramtally   | Mauritius      | Nothing to disclose  |
| Nathan       | Connell             | United States  | Takeda (consulting; advisory boards); Genentech (advisory boards); Octapharma (honoraria and travel support); Sanofi (advisory boards); Doximity (equity)  |
| Niamh        | Larkin              | Ireland        | Sobi (consultant; speaker fees); Sobi (grant)  |
| Nic          | Hawkes              | United Kingdom | Nothing to disclose  |
| Nicola       | Curry               | United Kingdom | Octapharma (consultancy); Sobi (support to attend conference); LFB (support to attend conference); Octapharma (support to attend conference); CSL Behring (Investigation led research)   |
| Nihal        | Bakeer              | United States  | Nothing to disclose  |
| Nikole       | Scappe-Hagen        | United States  | Nothing to disclose  |
| Nita         | Radhakrishnan Verma | India          | Nothing to disclose  |
| Noemy        | Diaz-Burgos         | United States  | Nothing to disclose  |
| Norjehan     | Yahaya              | Malaysia       | Nothing to disclose  |
| Novie Chozie | Chozie              | Indonesia      | Grifols (advisory board meeting, speaker fee); Pfizer (advisory board meeting, speaker fee); Novo Nordisk (advisory board meeting, speaker fee); Takeda (advisory board meeting, speaker fee); Octapharma (speaker fee)  |
| Nuria        | Fernandez Mosteirin | Spain          | Bayer (Advisor); CSL Behring<br>(Advisor); Octapharma (Advisor);<br>Sobi (Consultant   |
| Olav         | Versloot            | Netherlands    | Nothing to disclose  |
| Olga         | Benitez Hidalgo     | Spain          | Nothing to disclose  |
| Pam          | Wilton              | Canada         | Nothing to disclose  |
| Pamela       | Narayan             | India          | Nothing to disclose  |

| Patricia | Cabre      | Spain          | Nothing to disclose  |
|----------|------------|----------------|--|
| Patricia | Nally      | Argentina      | Nothing to disclose  |
| Paul     | McLaughlin | United Kingdom | Sobi (Research Grant support;<br>Speaker fees); Novo Nordisk<br>(Research Grant support; Speaker<br>fees); Pfizer (speaker fees); CSL<br>Behring (speaker fees); Roche<br>(speaker fees); National Institute for<br>Health and Care Research (research<br>grant) |
| Paula    | James      | Canada         | Star/Vega Therapeutics (consulting fees); Roche (consulting fees); Biomarin (consulting fees); Band/Guardian Therapeutics (consulting fees)  |
| Pedro    | Graça      | Mozambique     | Nothing to disclose  |
| Peter    | Aguero     | United States  | Sanofi (Honoraria); CSL Behring (Consulting)   |
| Peter    | Kouides    | United States  | Nothing to disclose  |
| Peter    | Lenting    | France         | To be confirmed  |
| Pierre   | Toulon     | France         | To be confirmed  |
| Pratima  | Chowdary   | United Kingdom | To be confirmed  |
| Radoslaw | Kaczmarek  | United States  | BioMarin (Consultation fees); Pfizer (Consultation fees); Bayer (Grant)  |
| Rajiv    | Pruthi     | United States  | To be confirmed  |
| Randall  | Curtis     | United States  | University of Southern California (Consult on research sponsored by unrestricted grants.); Patient outcomes research group (Coinvestigator on research funded by unrestricted grants.); HCD Economics (Consult on research sponsored by unrestricted grants.)    |
| Rebecca  | Schaffer   | United States  | Nothing to disclose  |
| Renchi   | Yang       | China          | Novo Nordisk (speaker/consultancy fees); Pfizer (speaker/consultancy fees); Roche (speaker/consultancy fees); Sanofi (speaker/consultancy fees); Takeda (speaker/consultancy fees)   |
| Richa    | Mohan      | India          | Nothing to disclose  |
| Richard  | Gorman     | United Kingdom | Nothing to disclose  |
| Riitta   | Lassila    | Finland        | Aplagon Ltd (Intellectual property);<br>CSL Behring (non-financial support);<br>Takeda (lecture fees); Pfizer (lecture<br>fees); Sobi (advisory board); Astra<br>Zeneca (advisory board; lecture<br>fees); Sanofi (DSMB; lecturing fees)                         |
| Robert   | Klamroth   | Germany        | Bayer (personal fees, grant); Biomarin (personal fees); CSL Behring (personal fees, grant); LFB  |

| Samantha        | Gouw            | Netherlands    | To be confirmed   |
|-----------------|-----------------|----------------|---|
| Salome          | Mekhuzla        | Canada         | To be confirmed   |
| Saliou          | Diop            | Senegal        | Novo Nordisk (speaker fees); Pfizer (advisory board); Novartis (speaker fees); Octapharma (speaker fees)  |
| Ruth            | Glover          | United Kingdom | To be confirmed   |
| Rubén           | Cuesta-Barriuso | Spain          | Roche (grant); Sobi (grant)   |
| Rubén           | Berrueco        | Spain          | for consulting, speaker)  Sobi (Grant; honoraria for speaking and consulting); Novo Nordisk (Honoraria for speaking and consulting); Roche (Grant; honoraria for speaking and consulting); Bayer (Honoraria for speaking and consulting); Pfizer (Honoraria for speaking); Takeda (Honoraria for speaking); Novartis (Grant; Honoraria for speaking); Amgen (Honoraria for speaking)  |
| Roshni Kulkarni | Kulkarni        | United States  | BioMarin (Personal fees- honoraria for consulting); CSL Behring (personal fees – speaker); Novo Nordisk (grant funding; personal fees – honoraria for consulting, speaker); Pfizer (grant funding; personal fees – honoraria for consulting); Sanofi Genzyme (grant funding; personal fees – honoraria for consulting speaker)  |
| Roseline        | D'Oiron         | France         | To be confirmed   |
| Rohini          | Dange           | India          | Nothing to disclose   |
| Roberto         | Ucero-Lozano    | Spain          | Roche (non-financial support)   |
| Robert          | Sidonio         | United States  | (personal fees, grant); Takeda (personal fees, grant)  Takeda (IIS and advisory boards (honararia)); Vega Therapeutics (advisory boards (honararia)); Genentech/Roche (advisory boards (honararia)); Hema Biologics/LFB (IIS and advisory boards (honararia)); Octapharma (IIS and advisory boards (honararia)); Pfizer (advisory boards (honararia)); Bayer (advisory boards (honararia)); HFA and ATHN (Receive personal fees for consultation) |
|                 |                 |                | (personal fees); Biotest (personal<br>fees); Chugai (personal fees); Grifols<br>(personal fees); Novo Nordisk<br>(personal fees, grant); Octapharma<br>(personal fees, grant); Pfizer<br>(personal fees); Roche (personal<br>fees); Sanofi (personal fees); Sobi  |

|           |                   |                | 1   |
|-----------|-------------------|----------------|---|
| Santiago  | Bonanad           | Spain          | Roche (Fees, travel and writing support); Sobi (Fees, travel support); Pfizer (fees); Bayer (fees); Octapharma (fees, writing support); Biomarin (fees); CSL Behring (fees); Novo Nordisk (fees); Takeda (fees)   |
| Sara      | Garcia-Barcenilla | Spain          | Roche (Travel, honoraria fee, assistance to congresses, consultant, training sessions, researcher); NovoNordisk (Travel, honoraria fee, assistance to congresses, consultant, training sessions, researcher); Novartis (Training sessions); Octapharma (Travel, assistance to congresses); Sobi (Travel, assistance to congresses, consultant); Pfizer (Travel, assistance to congresses) |
| Sara      | Portnoy           | United Kingdom | Nothing to disclose   |
| Sarah     | Noonberg          | United States  | To be confirmed   |
| Sarah     | O'Brien           | United States  | To be confirmed   |
| Sarah     | Whitaker          | United Kingdom | Sobi (personal fees); Chugai Roche (personal fees); Haemnet (personal fees); Sanofi (personal fees); MCI Suisse (personal fees); Pfizer (personal fees)   |
| Scott     | McLean            | United Kingdom | Nothing to disclose   |
| Sean      | Platton           | United Kingdom | Sanofi (Consultancy fees (2023)); Pfizer (Consultancy fees (2022)); Biomarin (Consultancy fees (2021)); Sysmex UK (Travel and accommodation(2023)); Diagnostica Stago UK (Travel and accommodation(2023)); American Society of Hematology (speaker fees (2023))   |
| Sébastien | Lacroix-Desmazes  | France         | Octapharma (lecturer); Topas (grant); 4DMT (advisory board)   |
| Sebastien | Lobet             | Belgium        | Nothing to disclose   |
| Shannon   | Jackson           | Canada         | Pfizer Global (advisory board); Pfizer<br>Canada (advisory board); Sanofi<br>Global (speaker); Roche Canada<br>(advisory board); Bayer Canada<br>(advisory board/speaker); Takeda<br>Canada (advisory board)  |
| Shannon   | Meeks             | United States  | Octapharma (research support; advisory boards); Genentech (research support; advisory boards); Teraimmune (consulting; advisory boards); Spark (consulting; advisory boards); Pfizer (consulting; advisory boards); CSL Behring (Advisory boards); Biomarin (advisory boards);  |

|          |                |                | Sanofi (advisory boards)  |
|----------|----------------|----------------|---|
| Sherry   | Herman-Hilker  | United States  | Partnersprn.org, partners in bleeding disorders education (honorarium for project); VWD Connect (speaking honorarium)   |
| Silvina  | Graña          | Argentina      | Nothing to disclose   |
| Sofía    | Pérez-Alenda   | Spain          | Pfizer (Pfizer global medical grant);<br>Takeda (sponsorship contribution);<br>Sobi (personal fees – educational<br>material, podcast)  |
| Sophie   | Susen          | France         | To be confirmed   |
| Stacy    | Croteau        | United States  | Spark Therapeutics (Research funds to institution); BioMarin (Consultant)   |
| Steve    | Pipe           | United States  | To be confirmed   |
| Sukesh   | Nair           | India          | To be confirmed   |
| Susan    | Cutter         | United States  | Pfizer (consultant)   |
| Suzanne  | O'Callaghan    | Australia      | Nothing to disclose   |
| Tadashi  | Matsushita     | Japan          | To be confirmed   |
| Tahira   | Zafar          | Pakistan       | Nothing to disclose   |
| Tatiana  | Bathfield      | Mauritius      | Nothing to disclose   |
| Tatjana  | Markovic       | Serbia         | Nothing to disclose   |
| Thomas   | Sannié         | France         | Nothing to disclose   |
| Tiffany  | Kaltenmark     | United States  | Nothing to disclose   |
| Ton      | Lisman         | Netherlands    | Nothing to disclose   |
| Toong    | Youttananukorn | Canada         | Nothing to disclose   |
| Tulasi   | Geevar         | India          | Nothing to disclose   |
| Vanessa  | Bouskill       | Canada         | Roche (Personal fees); Sanofi<br>(Personal fees); Novo Nordisk (non<br>financial support); Takeda (Personal<br>fees); Bayer (Personal fees)   |
| Vanessa  | Newman         | United Kingdom | To be confirmed   |
| Veena    | Selvaratnam    | Malaysia       | To be confirmed   |
| Verónica | Cerutti        | Spain          | Nothing to disclose   |
| Víctor   | Jiménez-Yuste  | Spain          | Pfizer (grant/research support; travel support; scientific advisory board); Shire (grant/research support; travel support; scientific advisory board); Novo Nordisk (grant/research support; travel support; scientific advisory board); Sobi (grant/research support; scientific advisory board); Octapharma (grant/research support; travel support; scientific advisory board); Grifols (travel support; scientific advisory board); CSL Behring (scientific advisory board); Roche (scientific advisory |

|                |                    |                | board); Biomarin (scientific advisory board); Sanofi (scientific advisory board)  |
|----------------|--------------------|----------------|---|
| Virginie       | Barbay             | France         | LFB (Consultant); Sobi (Consultant)   |
| Vishnu         | Sri Shanmuganathan | United Kingdom | Nothing to disclose   |
| Walid Saied    | Saied              | Tunisia        | Nothing to disclose   |
| Wolfgang       | Miesbach           | Germany        | Bayer (Research support; consulting; Speaker bureau); Biotest (research support; consulting, speaker bureau); CSL (Research support; consulting; Speaker bureau); LFB (Research support; consulting; Speaker bureau); Novo Nordisk (Research support; consulting; Speaker bureau); Octapharma (Research support; consulting; Speaker bureau); Pfizer (Research support; consulting; Speaker bureau); Takeda (Research support; consulting; Speaker bureau); Biomarin (Consulting; Speaker bureau); Biomarin (Consulting; Speaker bureau); Sanofi , (consulting; speaker bureau); Sanofi , (consulting); Chugai (consulting; speaker bureau); Uniqure (Consulting) |
| Yannick Collé  | Collé              | France         | Nothing to disclose   |
| Yu             | Yang               | China          | Nothing to disclose   |
| Zhengping      | Li                 | China          | Nothing to disclose   |
| Zikra Alkhayal | Alkhayal           | Saudi Arabia   | Nothing to disclose   |